Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis

Brain Research Reviews

Volumn 26, Issue 2-3, 1998, Pages 148-153

  Gainetdinov, Raul R ^a,c   Jones, Sara R ^a   Fumagalli, Fabio ^a,d   Wightman, R Mark ^b   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Dopamine; Dopamine transporter; Knockout mice; Microdialysis; Voltammetry; Volume transmission

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE DELETION; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NONHUMAN; POTENTIOMETRY; PRIORITY JOURNAL;

ANIMALS; BRAIN; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HOMEOSTASIS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; SYNAPSES;

EID: 0032077686     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(97)00063-5     Document Type: Conference Paper

References (45)

1. Agnati L.F., Zoli M., Stromberg I., Fuxe K. Intracellular communication in the brain: wiring versus volume transmission. Neuroscience. 69:1995;711-726.
2. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:1993;73-93.
3. M.J. Bannon, A.S. Freeman, L.A. Chiodo, B.S. Bunney, R.H. Roth, The pharmacology and electrophysiology of mesolimbic dopamine neurons, in: L.L. Iversen (Ed.), Handbook of Psychopharmacology, Vol. 19, Plenum Press, New York, 1987, pp. 329-374.
4. M.J. Bannon, J.G. Granneman, G. Kapatos, The dopamine transporter. Potential involvement in neuropsychiatric disorders, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven, New York, 1995, pp. 179-188.
5. Bannon M.J., Poosch M.S., Xia Y., Goebel D.J., Cassin B. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Nat. Acad. Sci. USA. 89:1992;7095-7099.
6. Bosse R., Fumagalli F., Jaber M., Giros B., Gainetdinov R.R., Wetsel W.C., Missale C., Caron M.G. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron. 19:1997;127-138.
7. A. Carlsson, Monoamines of the central nervous system: a historical perspective, in: H.Y. Meltzer (Ed.), Psychopharmacology: the Third Generation of Progress, Raven, New York, 1987, pp. 359-366.
8. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 201:1978;276-278.
9. Fuller R.W., Hemrick-Luecke S.K. Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science. 209:1980;305-307.
10. K. Fuxe, L.F. Agnati, Introduction, in: K. Fuxe, L.F. Agnati (Eds.), Volume transmission in the brain, Advances in Neuroscience, Vol. 1, Raven Press, New York, 1991, pp. 1-10.
11. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69:1997;1322-1325.
12. Garris P.A., Ciolkowski E.L., Pastore P., Wightman R.M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14:1994;6084-6093.
13. Garris P.A., Collins L.B., Jones S.R., Wightman R.M. Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J. Neurochem. 61:1993;637-647.
14. Garris P.A., Wightman R.M. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14:1994;442-450.
15. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. TiPS. 14:1993;43-49.
16. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
17. Goldstein M., Deutch A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6:1992;2413-2421.
18. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmac. Ther. 64:1994;291-369.
19. Jaber M., Jones S.R., Bosse R., Giros B., Caron M.G. Dramatic regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Soc. Neurosci. Abstr. 22:1996;1576.
20. Jones S.R., Garris P.A., Kilts C.D., Wightman R.M. Comparison of dopamine uptake in the basolateral amygdaloid nucleus, caudate putamen, and nucleus accumbens of the rat. J. Neurochem. 64:1995;2581-2589.
21. Jones S.R., Bowman B.P., Kuhn C.M., Wightman R.M. Development of dopamine neurotransmission and uptake inhibition in the caudate nucleus as measured by fast-cyclic voltammetry. Synapse. 24:1996;305-307.
22. Justice J.B. Jr. Quantitative microdialysis of neurotransmitters. J. Neurosci. Meth. 48:1993;263-276.
23. Kilts C.D., Anderson C.M., Ely T.D., Nishita J.K. Absence of synthesis modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J. Neurosci. 7:1987;3961-3975.
24. Kuczenski R., Segal D.S. An escalating dose/multiple high dose binge pattern of amphetamine administration results in differential changes in the extracellular dopamine response profiles in Caudate-Putamen and Nucleus Accumbens. J. Neurosci. 17:1997;4441-4447.
25. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513:1990;274-279.
26. 3H]dopamine over a wide range of concentrations by rat striatal preparations. Biochem. Pharmacol. 35:1986;4065-4071.
27. Moghaddam B., Roth R.H., Bunney B.S. Characterization of dopamine release in the rat medial prefrontal cortex as assesed by in vivo microdialysis: comparison to the striatum. Neuroscience. 36:1990;669-676.
28. Nirenberg M.J., Chan J., Pohorille A., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17:1997;6899-6907.
29. Pifl C., Giros B., Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinum. J. Neurosci. 13:1993;4246-4253.
30. Pileblad E., Fornstedt B., Clark D., Carlsson A. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. J. Pharm. Pharmacol. 37:1985;707-712.
31. M.E.A. Reith (Ed.), Neurotransmitter Transporters: Structure, Function and Regulation, Humana Press, Totowa, NJ, 1997.
32. Reith M.E.A., Xu C., Chen N.-H. Pharmacology and regulation of the neuronal dopamine transporter. Europ. J. Pharmacol. 324:1997;1-10.
33. R.H. Roth, J.D. Elsworth, Biochemical pharmacology of midbrain dopamine neurons, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven, New York, 1995, pp. 227-243.
34. Seeman P. Brain dopamine receptors. Pharmac. Rev. 32:1981;229-313.
35. L.S. Seiden, G.A. Ricaurte, Neurotoxicity of methamphetamine and related drugs, in: H.Y. Meltzer (Ed.), Psychopharmacology: the Third Generation of Progress, Raven, New York, 1987, pp. 359-366.
36. L.S. Seiden, K.E. Sabol, Neurotoxicity of methamphetamine-related drugs and cocaine, in: L.W. Chang, R.S. Dyer (Eds.), Handbook of neurotoxicology, Marcel Dekker, New York, 1995, pp. 825-843.
37. Shimada S., Kitayama S., Walther D., Uhl G. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Mol. Brain Res. 13:1992;359-362.
38. Sivam S.P. Dopaminergic modulation of serotonin metabolism in rat striatum: a study with dopamine uptake inhibitor GBR-12909. Life Sci. 56:1995;467-472.
39. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61:1993;1191-1206.
40. Walters J.R., Roth R.H. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 296:1976;5-14.
41. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. TiPS. 13:1992;193-200.
42. Wilson J.M., Levey A.I., Bergeron C., Kalasinsky K., Ang L., Peretti F., Adams V.I., Smialek J., Anderson W.R., Shannak K., Deck J., Niznik H.B., Kish S.J. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40:1996;428-439.
43. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Medicine. 2:1996;699-703.
44. Xia Y., Goebel D.J., Kapatos G., Bannon M.J. Quantification of rat dopamine transporter mRNA: effects of cocaine treatment and withdrawal. J. Neurochem. 59:1992;1179-1182.
45. S.R. Jones, R.R. Gainetdinov, M. Jaber, B. Giros, R.M. Wightman, M.G. Caron, Profound neuronal plasticity in response to inactivation of the dopamine transporter, Proc. Natl. Acad. Sci. USA, in press.